KMG Fiduciary Partners LLC Sells 1,151 Shares of Pfizer Inc. (NYSE:PFE)

KMG Fiduciary Partners LLC decreased its stake in Pfizer Inc. (NYSE:PFEGet Rating) by 2.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 38,876 shares of the biopharmaceutical company’s stock after selling 1,151 shares during the quarter. KMG Fiduciary Partners LLC’s holdings in Pfizer were worth $2,038,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Pfizer by 3.0% during the first quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock worth $24,801,210,000 after purchasing an additional 13,790,348 shares during the period. State Street Corp grew its holdings in Pfizer by 0.7% during the first quarter. State Street Corp now owns 286,854,205 shares of the biopharmaceutical company’s stock worth $14,850,442,000 after purchasing an additional 2,037,373 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Pfizer by 13.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after purchasing an additional 6,972,650 shares during the period. Norges Bank bought a new position in Pfizer during the fourth quarter worth about $3,351,891,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in Pfizer by 28.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 43,391,119 shares of the biopharmaceutical company’s stock worth $2,246,359,000 after purchasing an additional 9,537,621 shares during the period. Institutional investors own 67.90% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $44.57 on Friday. The firm’s fifty day moving average price is $48.40 and its two-hundred day moving average price is $50.33. The stock has a market cap of $250.14 billion, a PE ratio of 8.72, a PEG ratio of 0.54 and a beta of 0.70. Pfizer Inc. has a fifty-two week low of $40.94 and a fifty-two week high of $61.71. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42.

Pfizer (NYSE:PFEGet Rating) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. The firm had revenue of $27.74 billion for the quarter, compared to analysts’ expectations of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The company’s revenue was up 46.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.07 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 6.54 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 3.59%. Pfizer’s dividend payout ratio is 31.31%.

Analyst Ratings Changes

A number of research firms recently commented on PFE. Barclays set a $50.00 price target on Pfizer in a report on Thursday, September 1st. JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a report on Tuesday, June 28th. UBS Group set a $59.00 price objective on Pfizer in a report on Thursday, September 1st. SVB Leerink reduced their price objective on Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a report on Friday, July 29th. Finally, Morgan Stanley reduced their price objective on Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a report on Friday, July 8th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $57.00.

Pfizer Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.